Rheumatoid arthritis: Current perspectives on immunopathogenesis and therapeutic implications
PDF (Português (Brasil))

Keywords

rheumatoid arthritis; immunopathogenesis; treatment; management.

How to Cite

Cavalcante Calheiros de Melo, G., Vytor Cardoso Nobre, P., Acioli Lima de França , D., Farias Mota, M., Tenorio Costa, N., de Araujo Medeiros Pereira, M., Gabriel Oliveira Almeida , E., de Oliveira Santana Almeida , S., de Carvalho Moreira, J., Suellen Vieira Gonçalves, J., Clark de Carvalho Barbosa, L., Adrielle Oliveira Teodozio, M., & da Matta Monteiro Costa Pinheiro , R. (2024). Rheumatoid arthritis: Current perspectives on immunopathogenesis and therapeutic implications. Brazilian Journal of Implantology and Health Sciences, 6(5), 758–770. https://doi.org/10.36557/2674-8169.2024v6n5p758-770

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease, described by persistent inflammation of the synovial joints, which eventually leads to the destruction of joint tissue and functional disability. Objective: To evaluate the immunopathogenesis and therapeutic implications of rheumatoid arthritis. Methodology: This is a bibliographic review that included original articles and systematic reviews in English and Portuguese, which addressed the immunopathogenic aspects and management of RA, published between 2011 and 2024, selected from the PubMed, Scopus and SciELO databases. After careful selection, 23 articles were chosen to compose this bibliographic review. Results: There are several pathogenic factors that contribute to the advent of RA, such as infiltration of adaptive immune cells, the interaction between CD4+ T lymphocytes, "pathogenic" Th17 cells, and T regulatory cells (Treg) and B cells. some non-pharmacological measures, such as physical exercise and occupational therapy. Among pharmacological disciplines, the first line consists of DMARDs, as well as the use of NSAIDs and corticosteroids without pain control. Considerations: Understanding the pathogenesis of RA has advanced considerably, infiltration of adaptive immune cells revealing the complexity of the immunological mechanisms underlying the disease. Despite therapeutic advances, challenges remain, such as identifying early markers of the disease and developing more effective therapeutic interventions.

https://doi.org/10.36557/2674-8169.2024v6n5p758-770
PDF (Português (Brasil))

References

Aletaha, D., Ramiro, S. Diagnosis and Management of Rheumatoid Arthritis. JAMA, v. 320, p. 1360–1372, 2018. DOI: 10.1001/jama.2018.13103.

Brzustewicz, E. et al. Autoantibodies, C-reactive protein, erythrocyte sedimentation rate and serum cytokine profiling in monitoring of early treatment. Central European Journal of Immunology, v. 42, p. 259–268, 2017. DOI: 10.5114/ceji.2017.70968.

Bullock, J. et al. Rheumatoid arthritis: A brief overview of the treatment. Medical Principles and Practice, v. 27, p. 501–507, 2019. DOI: 10.1159/000493390.

Bywall, K. S. et al. Patient preferences on rheumatoid arthritis second-line treatment: A discrete choice experiment of Swedish patients. Arthritis Research & Therapy, v. 22, p. 1–10, 2020. DOI: 10.1186/s13075-020-02391-w.

Cramp, F. The role of non-pharmacological interventions in the management of rheumatoid-arthritis-related fatigue. Rheumatology, v. 58, p. 22–28, 2019. DOI: 10.1093/rheumatology/kez310.

Dekkers, J. S. et al. Breach of autoreactive B cell tolerance by post-translationally modified proteins. Annals of the Rheumatic Diseases, v. 76, p. 1449–1457, 2017. DOI: 10.1136/annrheumdis-2016-210772.

Edilova, M. I. et al. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomedical Journal, v. 44, p. 172–182, 2021. DOI: 10.1016/j.bj.2020.06.010.

Guo, Q. et al. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Research, v. 6, p. 1–15, 2018. DOI: 10.1038/s41413-018-0016-9.

Hua, C. et al. Glucocorticoids in rheumatoid arthritis: Current status and future studies. RMD Open, v. 6, e000536, 2020. DOI: 10.1136/rmdopen-2017-000536.

Kurowska, W. et al. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Central European Journal of Immunology, v. 42, p. 390–398, 2017. DOI: 10.5114/ceji.2017.72807.

Littlejohn, E. A., Monrad, S. Early Diagnosis and Treatment of Rheumatoid Arthritis. Primary Care: Clinics in Office Practice, v. 45, p. 237–255, 2018. DOI: 10.1016/j.pop.2018.02.010.

Lotfi, N. et al. Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update. Frontiers in Immunology, v. 10, p. 1265, 2019. DOI: 10.3389/fimmu.2019.01265.

Martin, A., Chopra, R., Nicassio, P. Nonpharmacologic pain management in inflammatory arthritis. Rheumatic Disease Clinics of North America, v. 47, p. 277–295, 2021. DOI: 10.1016/j.rdc.2020.12.009.

Mellado, M. et al. T Cell Migration in Rheumatoid Arthritis. Frontiers in Immunology, v. 6, p. 384, 2015. DOI: 10.3389/fimmu.2015.00384.

Moura, M. D. G. et al. Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol. Medicine, v. 97, e12658, 2018. DOI: 10.1097/MD.0000000000012658.

Ouboussad, L. et al. Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy. Frontiers in Medicine, v. 6, p. 45, 2019. DOI: 10.3389/fmed.2019.00045.

Rönnelid, J. et al. Autoantibodies in Rheumatoid Arthritis—Laboratory and Clinical Perspectives. Frontiers in Immunology, v. 12, p. 685312, 2021. DOI: 10.3389/fimmu.2021.685312.

Smolen, J. S. et al. Rheumatoid arthritis. Nature Reviews Disease Primers, v. 4, p. 1–23, 2018. DOI: 10.1038/nrdp.2018.1.

Smolen, J. S. et al. Rheumatoid arthritis. The Lancet, v. 388, p. 2023–2038, 2016. DOI: 10.1016/S0140-6736(16)30173-8.

Sokolove, J. et al. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis & Rheumatology, v. 63, p. 53–62, 2011. DOI: 10.1002/art.30081.

Tardito, S. et al. Macrophage M1/M2 polarization and rheumatoid arthritis: A systematic review. Autoimmunity Reviews, v. 18, p. 102397, 2019. DOI: 10.1016/j.autrev.2019.102397.

Wu, X. et al. Insight Into Non-Pathogenic Th17 Cells in Autoimmune Diseases. Frontiers in Immunology, v. 9, p. 1112, 2018. DOI: 10.3389/fimmu.2018.01112.

Yoshitomi, H. Regulation of Immune Responses and Chronic Inflammation by Fibroblast-Like Synoviocytes. Frontiers in Immunology, v. 10, p. 1395, 2019. DOI: 10.3389/fimmu.2019.01395.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Gabriel Cavalcante Calheiros de Melo, Paulo Vytor Cardoso Nobre, Daniella Acioli Lima de França , Marcos Farias Mota, Nelson Tenorio Costa, Martha de Araujo Medeiros Pereira, Erik Gabriel Oliveira Almeida , Sarah de Oliveira Santana Almeida , Juliana de Carvalho Moreira, Jéssica Suellen Vieira Gonçalves, Lydio Clark de Carvalho Barbosa, Maria Adrielle Oliveira Teodozio, Rafaela da Matta Monteiro Costa Pinheiro